Carasent ASA (CARA) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Carasent ASA stock SEK 11.41, price SEK 25.60, that is 55.4% below the price, quality 61 out of 100. Rating: strongly overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range kr 9.91 – kr 42.81 · fair‑value band kr 6.56 – kr 14.83 · the kr 25.60 price screens above the kr 11.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Carasent in your weekly email
Every Wednesday you see whether Carasent is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Carasent AB (publ) provides cloud based electronic health record (EHR) systems solutions and platform services for healthcare sector in Nordics and Germany. The company offers Webdoc, Webcur, Metodika, Ad Curis, Ad Opus, and Data-AL solutions.
Show moreShow less
It also provides Medrave, Vårdrummet, Ad Voca, and HPI Plustoo services, as well as an ecosystem of platform services, including solutions for patient communication and business intelligence. The company was founded in 1997 and is headquartered in Gothenburg, Sweden.
Stock analysis
Carasent ASA (CARA) currently trades at kr 25.60, while our model-based Fair Value estimate is kr 11.41, 55% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of kr 15.43 per share, and 0 of the 15 models we run sit above the kr 25.60 price.
Bear case: the Asset-Based group reads lowest at kr 1.25, and 15 of the 15 models stay below the price. Data coverage for this calculation is medium.
Scenario range: kr 6.56 (bear) to kr 14.83 (bull), the price of kr 25.60 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Carasent ASA reported revenue of 344M SEK in FY2025 versus 137M SEK in FY2021, a compound +25.8%/yr. Reported net income was 34.7M SEK in FY2025.
Key figures
Market cap 1.9B SEK (≈ $191M) Micro · P/E ratio 44.9 · P/S ratio 4.84 · EPS (TTM) kr 0.5700 · Net margin 10.1% · Return on equity 4.8% · Return on assets (EBIT) −2.0% (5-year average) · Operating margin 8.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).
What moves the price
The share trades about 12% below its 52-week high and 16% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −55%, CARA screens richer than that median.
Fair Value models
Bearkr 6.56Fair Value kr 11.41Bullkr 14.83
Price kr 25.60 · Downside -55.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (kr 0.4872 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+28.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+37.3%
Start year 2020 (pandemic). Over 10 years: +1.3% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.5%
’13
’14
’15
’16
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
≈ +44.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year≈ +44.6%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 44.6% / −20.5%
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 3%
⚠ Revenue per share shrinking 10.5%/yr over ~11Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
⚠ Base effect: the rate starts in the earnings trough around 2020 (starting value 0.079 per share, median 1.98 in 2015 to 2018). It measures the recovery from the trough, not lasting growth.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score61 · Above median
Fair Value upside−55.4% · Below median
Profitability
Return on equity (12 months)4.8% · Above median
Return on assets3.7% · Above median
Net margin (12 months)10.1% · Above median
Operating margin (12 months)8.4% · Above median
Growth and dividend
Revenue growth (quarter YoY)31.6% · Top 25%
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/E (12 months)44.9× · Pricier than median
P/B2.33× · Pricier than median
P/S (12 months)4.84× · Pricier than median
EV/EBITDA57.0× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 46
PAST (return on equity)19· sector 10
HEALTH (low debt)100· sector 98
DIVIDEND (yield)0· sector 41
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Carasent ASA Fair Value". https://www.fairvalue-calculator.com/stock/CARA
Frequently asked questions
Is Carasent ASA (CARA) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of kr 11.41 versus a price of kr 25.60, about 55% lower (overvalued).
What is the fair value of CARA?
Our model-based fair value for Carasent ASA is kr 11.41 (as of Nov 4, 2026), built from audited fundamentals. The current price: kr 25.60.
What is the quality score of CARA?
Carasent ASA has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Carasent ASA (CARA)?
Our model-based price target is the fair value of kr 11.41 (as of Nov 4, 2026) from 15 valuation models. Cautious scenario kr 6.56, optimistic scenario kr 14.83. It is a calculation from audited fundamentals, not an analyst target.
What is the Carasent ASA stock forecast for 2026?
Our models put fair value at kr 11.41, about 55% lower versus a price of kr 25.60 (overvalued). Cautious scenario kr 6.56, optimistic scenario kr 14.83. The calculation is refreshed regularly with new filings.
What is the revenue of Carasent ASA (CARA)?
Carasent ASA reported trailing-twelve-month revenue of about 390M SEK (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Carasent ASA (CARA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Carasent ASA it is kr 11.41 per share (as of Nov 4, 2026), against a price of kr 25.60. It is the blended result of 15 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Carasent ASA stock overvalued or undervalued in 2026?
As of Nov 4, 2026, CARA trades above its calculated fair value: price kr 25.60, fair value kr 11.41, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CARA?
No. The price is what the market pays today (kr 25.60); the fair value is what the company's own numbers justify (kr 11.41). For Carasent ASA the two are kr 14.19 per share apart. That gap is exactly why we show both numbers side by side.
How much is Carasent ASA worth?
The market values Carasent ASA at about 1.9B SEK (market capitalisation, as of Nov 4, 2026). Per share that is kr 25.60; our models calculate a fair value of kr 11.41 per share.
What do the bullish and bearish scenarios say about CARA?
Our models span a range for Carasent ASA: cautious scenario kr 6.56, base kr 11.41, optimistic kr 14.83 per share (as of Nov 4, 2026, price kr 25.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CARA?
Carasent ASA trades at a price-to-earnings ratio of 44.9 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 11.41 is built from several models across several years. Other multiples: P/B 2.3, P/S 4.8, EV/EBITDA 57.0.
How solid is the balance sheet of Carasent ASA (CARA)?
Balance-sheet figures for Carasent ASA (as of Nov 4, 2026): return on equity 4.8%. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is CARA from its 52-week high?
Carasent ASA trades at kr 25.60, about 12% below its 52-week high of kr 29.00 and 16% above the low of kr 22.00 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 11.41 is for.
Which stocks are comparable to Carasent ASA?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Carasent ASA stock attractive at the current price?
The data as of Nov 4, 2026: price kr 25.60, calculated fair value kr 11.41 (−55%), Quality Score 61/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CARA calculated?
We run Carasent ASA through 15 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of kr 11.41 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Carasent ASA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Carasent ASA (CARA)?
The closing price on Nov 6, 2026 was kr 25.60. Our model-based fair value is kr 11.41, about 55% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Carasent ASA right now?
The price sits above even our optimistic bull case (kr 14.83). The favourable scenario is already priced in. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 6.56 to kr 14.83) leaves room in how you read the outcome.
Key figures of Carasent ASA
How large is the market capitalisation of Carasent ASA (CARA)?
The market capitalisation of Carasent ASA is 1.9B SEK (≈ $191M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Carasent ASA (CARA)?
The price-to-sales ratio of Carasent ASA is 4.84 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Carasent ASA (CARA)?
Earnings per share at Carasent ASA are kr 0.5700 (price ÷ EPS = P/E 44.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Carasent ASA (CARA)?
The net margin of Carasent ASA is 10.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Carasent ASA (CARA)?
The return on equity (ROE) of Carasent ASA is 4.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Carasent ASA (CARA)?
On an EBIT basis the return on assets of Carasent ASA is −2.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Carasent ASA (CARA)?
The operating margin of Carasent ASA is 8.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Carasent ASA (CARA)?
Revenue at Carasent ASA is growing +31.6% versus a year earlier (3y avg +20.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Carasent ASA (CARA)?
Earnings per share at Carasent ASA are growing −25.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Carasent ASA (CARA) generate?
The free cash flow of Carasent ASA is −476K SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Carasent ASA (CARA) hold?
Carasent ASA holds more cash than debt, 108M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Carasent ASA in the live analysis
One click puts Carasent ASA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 4, 2026